Benzinga | Apr 26, 2021 09:51AM EDT

Mizuho Maintains Buy on Biohaven Pharma Hldgs, Lowers Price Target to $98

Mizuho analyst Vamil Divan maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Buy and lowers the price target from $103 to $98.